AllianceBernstein’s Trillium Therapeutics Inc. TRIL Stock Holding History

AllianceBernstein’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,209,595	Closed	-$21.2M	–	3396
2021 Q3	$21.2M	Buy	1,209,595 +1,109,295	+1,106%	+$13M	0.01%	921
2021 Q2	$973K	Buy	+100,300	New	+$944K	﹤0.01%	2545
2020 Q2	–	Sell	-2,363,767	Closed	-$9.55M	–	3288
2020 Q1	$9.55M	Buy	+2,363,767	New	+$8.94M	0.01%	930

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

AllianceBernstein's TRIL Position: Q4 2021 in Review

AllianceBernstein sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 1,209,595 shares — an estimated $21.2M sold.

AllianceBernstein first reported a position in TRIL in Q1 2020 and held it in 3 quarters. The position peaked at $21.2M in Q3 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

AllianceBernstein reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
AllianceBernstein sold 1,209,595 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $21.2M.
AllianceBernstein first reported a position in Trillium Therapeutics Inc. in Q1 2020 and held it in 3 quarters.
AllianceBernstein's Trillium Therapeutics Inc. position peaked at $21.2M in Q3 2021.
2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on AllianceBernstein's 13F filing for Q4 2021, filed 14 Feb 2022.